Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), retaining the price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Inmune Bio’s ongoing Phase 2 trial of their lead asset, XPro, targeting early-mild Alzheimer’s disease. The upcoming release of trial data is anticipated to be a significant catalyst for the company’s stock, especially considering the high short interest, which could lead to a short squeeze if the results are favorable.
Moreover, the trial’s design is robust, utilizing the novel Early Mild Alzheimer’s Cognitive Composite (EMACC) as the primary endpoint. This approach aims to provide more objective data compared to traditional measures, potentially reshaping how cognitive decline is assessed in early Alzheimer’s. The anticipation of top-line results and the innovative methodology employed in the trial contribute to the positive outlook for Inmune Bio’s stock.
In another report released on June 4, Lucid Capital also initiated coverage with a Buy rating on the stock with a $25.00 price target.
INMB’s price has also changed dramatically for the past six months – from $5.080 to $8.020, which is a 57.87% increase.